**Core tip:** This study was an updated meta-analysis of primary prevention and the first meta-analysis of secondary prevention of variceal bleeding in cirrhotic patients. Seven relevant randomized controlled trials were included. Based on the pooled analysis, carvedilol had similar efficacy to endoscopic variceal ligation (EVL) in preventing the first variceal hemorrhage in cirrhosis patients with esophageal varices. Carvedilol was superior to EVL for secondary prevention of variceal bleeding in regard to all-cause mortality reduction by 49% (RR: 0.51, 95%CI: 0.33--0.79).

INTRODUCTION
============

Variceal hemorrhage is associated with high mortality and is the cause of death for 20--30% of patients with cirrhosis\[[@B1]\]. The use of nonselective β blockers (NSBBs) or endoscopic variceal ligation (EVL) is recommended to prevent primary variceal bleeding in patients with medium to large esophageal varices\[[@B2]\]. Meanwhile, a combination of EVL and NSBBs (*i.e*., propranolol or nadolol, with carvedilol as an alternative) is the standard approach to prevent rebleeding. Treatment selection is based on the availability of local resources and expertise, patient characteristics and preferences, contraindications, and side-effects\[[@B3]\] .

NSBBs reduce portal pressure by decreasing cardiac output (β-1 effect) and, more importantly, by initiating splanchnic vasoconstriction (β-2 effect), thus causing a reduction in portal vein pressure. A decrease in the hepatic venous pressure gradient of \< 20% or even \< 10% from baseline significantly minimizes the risk of the first variceal hemorrhage\[[@B4],[@B5]\].

Carvedilol, given its additional α-blocking component, has been reported to have higher efficacy than other NSBBs in reducing intrahepatic vascular resistance. A significant difference in overall mortality, bleeding-related mortality, and upper gastrointestinal bleeding between patients treated with carvedilol or EVL to prevent first variceal hemorrhage was not seen in a previous systematic review. However, only two primary prevention studies were included in the review. On the other hand, until present, there is no systematic review or meta-analysis comparing carvedilol with EVL for the secondary prevention of variceal bleeding\[[@B6]-[@B8]\].

We hypothesized that there was no difference between carvedilol and EVL intervention for primary and secondary prevention of variceal bleeding in cirrhosis patients. In many developing countries, EVL intervention is only available at specific secondary or tertiary healthcare centres. We presumed that carvedilol may be the best prevention strategy of variceal bleeding, especially in hospitals that are unable to offer EVL. Therefore, we performed this review with the inclusion of subsequent trials to summarize and update the evidence.

The study objective was to compare the efficacy of carvedilol and EVL for primary and secondary prevention of variceal bleeding in cirrhotic patients

MATERIALS AND METHODS
=====================

Study sample, design, and setting
---------------------------------

Patients with cirrhosis and portal hypertension, regardless of aetiology and severity, with or without a history of variceal bleeding, and aged ≥ 18 years old were included in this systematic review and meta-analysis. Only randomized controlled trials (RCTs) that compared the efficacy of carvedilol and that of EVL for primary and secondary prevention of variceal bleeding and mortality in patients with cirrhosis and portal hypertension were considered, irrespective of publication status, year of publication, and language.

Treatment outcomes
------------------

A comparison of the primary outcome (bleeding events, all-cause mortality, and bleeding-related mortality) was made for patients with and without a history of variceal bleeding. A bleeding incident was defined as hematemesis or melena and was detected by endoscopic procedure or signs of hemorrhage. Bleeding from the band ligation was also counted. All-cause mortality meant death that occurred in each of the included studies and until follow-up completion.

Serious adverse events, non-serious adverse events, and compliance and treatment failure were secondary outcomes. An adverse event was considered be serious if it led to death, was life-threatening, or caused persistent disability.

Search strategy and literature review
-------------------------------------

Two independent reviewers searched the Medline, Cochrane Central Register of Controlled Trials (CENTRAL), and EMBASE journal databases from March to August 2018 (Table [1](#T1){ref-type="table"}). The reference lists of the retrieved articles were perused for potentially relevant studies. Abstracts and other gray literatures were also included through a manual and electronic search of the clinical trial registries and electronic databases.

###### 

Search strategy

  **Journal database**                                                                                                              **Search Terms**                                                                                                                                                           **Articles**
  --------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------
  CENTRAL                                                                                                                           (Cirrhosis OR "esophageal varices" OR "oesophageal varices") AND (carvedilol) AND (ligation OR "variceal band ligation" OR "endoscopic variceal ligation" OR VBL OR EVL)   20
  MEDLINE                                                                                                                           (Cirrhosis OR "esophageal varices" OR "oesophageal varices") AND (carvedilol) AND (ligation or "variceal band ligation" OR "endoscopic variceal ligation" OR VBL OR EVL)   5
  EMBASE *via* Ovid                                                                                                                 Cirrhosis AND Carvedilol AND Ligation                                                                                                                                      3
  A manual search of abstracts and citation index from identified paper's reference list and *via* https://library.sydney.edu.au/   "portal hypertension", "cirrhosis", "carvedilol", "endoscopic variceal ligation"                                                                                           54

Selection of study
------------------

Relevant studies, screened based on the title and abstract, were selected after conducting an electronic search. Studies on animals and review articles were excluded. Disagreement was resolved through discussion, failing which a third reviewer was consulted. The study selection process was plotted using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. The relevant studies were independently appraised using an Oxford Centre for Evidence-Based Medicine critical appraisal tool.

Assessment of bias
------------------

Risk of bias was independently determined using the Cochrane risk-of-bias tool. The data were then included in a table. Risk of bias was classified as low, high, or unclear. Disagreement was resolved through discussion, failing which a third reviewer was consulted.

Statistical analysis
--------------------

Risk ratios (RR) and 95%CI were used to calculate the dichotomous data. RRs with 95%CI were used as relevant effect measures for variceal bleeding, all-cause mortality, and bleeding-related mortality. Statistical analysis was performed according to the Cochrane Handbook for Systematic Reviews of Interventions and using Review Manager^®^ version 5.3 guidelines.

A random-effects model was chosen a priori for the entire analysis. The χ^2^ and *I*^2^ statistics were calculated. *P* \< 0.10 or *I*^2^ of \> 60% was considered to indicate substantial heterogeneity. *I*^2^ of \> 40% indicated moderate heterogeneity. Analysis was carried out using a ﬁxed-effects model, in the absence of statistically signiﬁcant heterogeneity, and a random-effects model in the case of signiﬁcant heterogeneity. For the subgroup analysis, *P* \< 0.05 was considered to denote a difference that was statistically significant between the subgroups. We assessed the quality of evidence using Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach and created 'Summary of findings' table.

Our initial intention was to perform sensitivity analysis of heterogeneity found in the pooled studies through the exclusion of studies with low-quality results. However, this did not occur owing to a paucity of data. Subgroup analysis was conducted of the primary bleeding outcomes based on the grade of varices.

RESULTS
=======

Five, twenty, and three relevant references were identified in the Medline, CENTRAL, and EMBASE *via* Ovid databases, respectively. Fifty-four of them were selected through a manual search of the references lists in the identiﬁed papers. Thirty-five studies were duplicates and were removed. The abstracts were also filtered, leading to the removal of a further 22 studies that met the exclusion criteria for various reasons; *i.e*., carvedilol or EVL were not used as interventions, the study design was not an RCT, or the research had been withdrawn or was ongoing. Thirteen full-text studies were assessed for eligibility. Six of these were excluded, primarily because either EVL or carvedilol were not evaluated, or carvedilol was assessed but in combination with other drugs (Figure [1](#F1){ref-type="fig"}).

![The results of the literature search process used in the current study, depicted using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.](WJH-11-464-g001){#F1}

Seven RCTs were included in the current study. Primary prevention was assessed in four trials\[[@B9]-[@B12]\], and secondary prevention was evaluated in three\[[@B9]-[@B15]\] (Table [2](#T2){ref-type="table"}). Three of the studies were deemed to be of fair quality, and the remaining one was determined to be of low quality when measured using the Cochrane risk-of-bias tool (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}).

###### 

Characteristic of included studies

  **Ref**.                      **History of variceal bleeding**   **Treatment groups**   **Age (mean** ± SD, **yr)**   ***n***   **Dosage / method**                                                                     **Follow up** **(mo)**
  ----------------------------- ---------------------------------- ---------------------- ----------------------------- --------- --------------------------------------------------------------------------------------- ------------------------
  Tripathi et al\[[@B9]\]       No                                 Carvedilol             54.2 ± 9.4                    77        6.25 mg (starting dose) daily, with target dose of 12.5 mg daily                        24
                                                                   EVL                    54.5 ±11.1                    75        Every two weeks until eradication                                                       24
  Shah et al\[[@B10]\]          No                                 Carvedilol             48.3 ± 11.3                   82        6.25 mg daily, with target dose of 6.25 mg twice a day                                  up to 24
                                                                   EVL                    47.2 ± 13.2                   86        Every three weeks until eradication                                                     up to 24
  Khan et al\[[@B12]\]          No                                 Carvedilol             52.1 ± 14.7                   125       12.5 mg daily                                                                           6
                                                                   EVL                    54.1±14.3                     125       Not mentioned                                                                           6
  Abd ElRahim et al\[[@B11]\]   No                                 Carvedilol             51.2 ± 11.0                   84        starting dosage of 6.25 mg daily, titrated up every 4 days to reach up to 12.5--50 mg   up to 12
                                                                   EVL                    50.6 ± 5.9                    88        Every two weeks until eradication                                                       up to 12
  Smith et al\[[@B15]\]         Yes                                Carvedilol             51 ± 10.9                     32        6.25 mg daily, with target dose 12.5 of mg daily                                        29
                                                                   EVL                    50 ± 13.0                     31        Not mentioned                                                                           29
  Stanley et al\[[@B14]\]       Yes                                Carvedilol             51.4 ± 10.8                   33        6.25 mg daily, with target dose 12.5 of mg daily                                        up to 60
                                                                   EVL                    49.6 ± 12.87                  31        Every two weeks until eradication                                                       up to 60
  Kumar et al\[[@B13]\]         Yes                                Carvedilol             44.1 ± 8.5 (overall)          47        Not mentioned                                                                           11.1 - 21.7
                                                                   EVL                    44.1 ± 8.5 (overall)          56        Not mentioned                                                                           11.1 - 21.7

EVL: Endoscopic variceal ligation.

![A risk of bias graph showing the researchers' opinions on each risk of bias item (presented as percentages across all the seven included studies).](WJH-11-464-g002){#F2}

![A risk of bias summary showing the researchers' opinions on each risk of bias item for each of the seven included studies.](WJH-11-464-g003){#F3}

In the four studies that assessed primary prevention, 368 patients were randomised to carvedilol and 374 patients to EVL. The length of follow-up in the studies varied from 6--24 mo. The mean age of the participants was 47--52 years. Majority of study subjects in two of the trials were classified as Child class A (Child-Pugh Score) and as Child class C in one trial, while cirrhosis was not classified in the fourth research. Most of the trials included cirrhosis patients with medium to large varices (grade II or higher)\[[@B10]-[@B12]\], but one study included patients with grade I and II esophageal varices\[[@B13]\]. There was no difference for bleeding incidence (RR: 0.74, 95%CI: 0.37--1.49), all-cause mortality (RR of 1.10, 95%CI: 0.76-1.58), and bleeding-related mortality (RR: 1.02, 95%CI: 0.34--3.10) between carvedilol group and EVL (Figure [4](#F4){ref-type="fig"} A-C). Subgroup analysis was conducted on participants with medium to large esophageal varices (grade II or larger), and the differences between the groups were also without statistical significance (RR: 0.89, 95%CI: 0.55--1.43). There was little to no evidence of subgroup differences between Grade I and Grade II varices or higher (χ^2^ = 2.19, degrees of freedom = 1, *P* = 0.14). The differences might be moderate (*I*^2^ = 54.4%) (Figure [4A](#F4){ref-type="fig"}).

![Meta-analysis forest plot of primary outcomes in primary prevention studies. A: Variceal bleeding; B: All-cause mortality; C: Bleeding-related mortality.](WJH-11-464-g004){#F4}

During the follow-up, hypotension was seen to be the most common side-effect of carvedilol treatment, followed by bradycardia, and asthmatic attack\[[@B11]\]. Following analysis of the primary prevention studies, a 4.18 times higher risk of treatment-related side-effects was attributed to the carvedilol group (95%CI: 2.19--7.95, *P* ≤ 0.001) (Figure [5](#F5){ref-type="fig"} A). By contrast, EVL was shown to be associated with serious adverse events (*i.e*., chest pain that required medication) in 20% of the participants, compared to 0% of the patients in the carvedilol group (*P* ≤ 0.001) in another study\[[@B10]\]. However, subjects in the carvedilol group experienced more non-serious adverse events, including dyspnea and nausea (*P* = \< 0.001). Patient compliance with the treatment was similar between the two groups when the primary prevention studies were analyzed (*P* = 0.32) (Figure [5](#F5){ref-type="fig"} B).

![Meta-analysis forest plot of secondary outcomes in primary prevention studies. A: Side-effects of treatment; B: Compliance.](WJH-11-464-g005){#F5}

The randomization of 230 participants took place in the three trials in which secondary prevention was assessed. The mean age of the participants in the studies ranged from 44--52 years. A median Child-Pugh score of 9 was attained, with a mean follow-up period of 16--30 mo. There was no difference between the two interventions with respect to rebleeding incidence (RR: 1.10, 95%CI: 0.75--1.61) (Figure [6](#F6){ref-type="fig"} A). The fixed-effects model showed that carvedilol decreased all-cause mortality by 49% (RR: 0.51, 95%CI: 0.33--0.79) (Figure [6](#F6){ref-type="fig"} B) without significant heterogeneity (χ^2^ = 0.04, *P* = 0.980, *I*^2^ = 0%). Elsewhere, in a study on secondary prevention, Stanley et al\[[@B14]\] reported a similar incidence of serious adverse events in both intervention groups (*P* = 0.97). However, Kumar et al\[[@B13]\] noted considerably more side-effects (28%) due to carvedilol compared to EVL (2%) (*P* ≤ 0.05).

![Meta-analysis forest plot of primary outcomes in secondary prevention studies. A: Variceal rebleeding; B: All-cause mortality.](WJH-11-464-g006){#F6}

DISCUSSION
==========

In this study, we found no significant differences in the incidence of variceal bleeding, all-cause mortality, and bleeding-related mortality between carvedilol *vs* EVL for primary prevention strategy. This finding was consistent with the subsequent subgroup analysis of participants with medium to large esophageal varices (grade II or higher). This finding was also similar to that reported in a previous meta-analysis\[[@B8]\], but the current study extended to an analysis of the side-effects that arose from the interventions and patient compliance with the medication.

To the best of our knowledge, this study is the first meta-analysis to have assessed the efficacy of carvedilol *vs* that of EVL for secondary prevention of variceal bleeding. Based on our pooled analysis, although there was no significant difference regarding incidence, carvedilol may be superior compared to EVL by significantly reducing all-cause mortality. Unfortunately, the relevant data needed to elucidate this finding were lacking in the review. In a study conducted by Stanley, most deaths in the carvedilol group were related to bleeding (15%), whereas only 3% of deaths were due to bleeding in the EVL group. None of the patients in the carvedilol group died of liver-related causes not due to bleeding, whereas the latter was responsible for the deaths of six of the 31 (19%) patients in the EVL group. It is assumed that this result can be explained by the systematic effect of carvedilol in reducing portal pressure in patients with cirrhosis.

Carvedilol, an NSBB with weak intrinsic anti-α1-adrenergic activity, is known to effect a reduction in portal pressure with added vasodilatory α-adrenergic blocking activity. The α1-adrenergic receptor located in the splanchnic vascular smooth muscles and vascular smooth muscle at other sites, such as the genitourinary tract. Blocking the α1-adrenergic receptors leads to a reduction in intrahepatic vascular tone. Therefore, the α1- and β-receptor-blocking properties of carvedilol can lead to superior reduction in portal pressure compared to conventional NSBBs (*i.e*., propranolol or nadolol)\[[@B16]\].

The current recommendation for the prevention of variceal rebleeding in cirrhosis patients is to use a combination of EVL and NSBBs (*i.e*., propranolol or nadolol). This study revealed that carvedilol is superior to EVL alone for secondary prevention of variceal bleeding in regard to all-cause mortality reduction. Regarding this finding, we encourage that RCTs comparing efficacy of carvedilol *vs* combination therapy of EVL and NSBBs should be conducted to strengthen the evidence. This current study finding may be of use to physicians working in rural areas or hospitals where an EVL intervention is unlikely\[[@B17]\].

In the primary prevention studies, patient compliance was similar in both groups despite a greater number of side-effects being seen in the carvedilol group. This indicates that the side-effects were nevertheless tolerable to the participants. In the secondary prevention studies, the data on serious adverse events and side-effects of both interventions were still insufficient. Further studies are needed to comprehensively assess the side-effects of each intervention.

There are several limitations in this systematic review and meta-analysis that bear mentioning. First, we could not retrieve complete data from some included studies which hindered us to do some subgroup analysis, such as subgroup analysis of cirrhosis severity or numbers of EVL procedure performed. Most of the included studies also did not perform specific analysis regarding this particularly topic. Second, the numbers of available clinical trials are relatively limited which also hindered us to perform sensitivity analysis for this study.

The quality of evidence of primary prevention for variceal bleeding is low. The quality is reduced due to lack of blinding in the included studies. On the contrary, the quality of evidence for the all-cause mortality and the bleeding-related mortality in primary prevention is high as the included studies showed low risk of bias. The quality of evidence of secondary prevention for rebleeding is low, because some of the included studies showed unclear methods while conducting the studies (Table [3](#T3){ref-type="table"}).

###### 

Summary of findings for the main comparison

  **Outcomes**                                       **Relative effect**   **Participants**   **Quality of the evidence**   **Comments**
  -------------------------------------------------- --------------------- ------------------ ----------------------------- ------------------------------
  Variceal bleed in primary prevention (Grade I)     RR 0.38               250                ++−−                          Benefit for Carvedilol group
  (0.15-0.93)                                        (1 Study)             low                                              
  Variceal bleed in primary prevention (Grade II)    RR 0.92               492                +++−                          
  (0.42-2.41)                                        (3 Studies)           moderate                                         
  All-cause mortality in primary prevention          RR 1.10               320                ++++                          
  (0.76-1.58)                                        (2 Studies)           high                                             
  Bleeding-related mortality in primary prevention   RR 1.02               320                ++++                          
  (0.34-3.10)                                        (2 Studies)           high                                             
  Side effect of treatment in primary prevention     RR 4.18               276                +++−                          Benefit for EVL group
  (2.19-7.95)                                        (2 Studies)           moderate                                         
  Compliance in primary prevention                   RR 0.90               122                +++−                          
  (0.73-1.11)                                        (2 Studies)           low                                              
  Rebleeding events in secondary prevention          RR 1.10               230                ++−−                          
  (0.75-1.61)                                        (3 Studies)           low                                              
  All-cause mortality in secondary prevention        RR 0.51               230                ++−−                          Benefit for Carvedilol group
  (0.33-0.79)                                        (3 Studies)           low                                              

GRADE: Grading of Recommendations, Assessment, Development and Evaluation; Patient or population: Portal hypertension or cirrhosis patients; Comparison: Endoscopic variceal ligation; Settings: Secondary or tertiary hospital; Intervention: Carvedilol. GRADE Working Group grades of evidence. High quality: Further research is very unlikely to change our confidence in the estimate of effect; Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; Very low quality: We are very uncertain about the estimate.

In conclusion, carvedilol had similar efficacy to EVL in preventing the first variceal bleeding in cirrhosis patients with esophageal varices. We considered that carvedilol was superior to EVL alone for secondary prevention of variceal bleeding in regard to all-cause mortality reduction.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Variceal hemorrhage is associated with high mortality and is the cause of death for 20%--30% of patients with cirrhosis. Either traditional nonselective β blockers (NSBBs) (*i.e*. propranolol or nadolol), carvedilol, or endoscopic variceal ligation (EVL) is recommended for primary prevention of variceal bleeding in patients with medium to large esophageal varices. Meanwhile, combination of EVL and NSBBs is the recommended approach for the secondary prevention. Carvedilol has greater efficacy than other NSBBs as it decreases intrahepatic resistance. We hypothesized that there was no difference between carvedilol and EVL intervention for primary and secondary prevention of variceal bleeding in cirrhosis patients.

Research motivation
-------------------

Some of the major drawbacks of EVL are invasive, costly, and unavailable in many areas, especially in developing countries. A better understanding of the efficacy of carvedilol compared to EVL might provide less invasive and more accessible prevention strategy for variceal bleeding in cirrhosis patients.

Research objectives
-------------------

We conducted this meta-analysis to evaluate the efficacy of carvedilol compared to EVL for primary and secondary prevention of variceal bleeding in cirrhotic patients with esophageal varices

Research methods
----------------

We searched relevant literatures in major journal databases (CENTRAL, MEDLINE, and EMBASE) from March to August 2018. Only randomized controlled trials (RCTs) that compared the efficacy of carvedilol and that of EVL for primary and secondary prevention of variceal bleeding and mortality in patients with cirrhosis and portal hypertension were considered, irrespective of publication status, year of publication, and language.

Research results
----------------

Seven RCTs were included in this meta-analysis. For primary prevention strategy, we found no significant difference between carvedilol and EVL on the events of variceal bleeding, all-cause mortality, and bleeding-related mortality. For secondary prevention strategy, we found no difference between two interventions for the incidence of rebleeding. Interestingly, compared to EVL, carvedilol decreased all-cause mortality by 49% (RR: 0.51, 95%CI: 0.33-0.79), with little or no evidence of heterogeneity.

Research conclusions
--------------------

Carvedilol had similar efficacy to EVL in preventing the first variceal bleeding in cirrhosis patients with esophageal varices. In clinical practice, the use of carvedilol or EVL for prevention of first variceal bleeding may depends on physicians' and patients' preference. For prevention of rebleeding, we considered that carvedilol was superior to EVL alone in regard to all-cause mortality reduction.

Research perspectives
---------------------

This study demonstrated significant benefit of using carvedilol for secondary prevention of variceal bleeding in cirrhosis patients. We highly suggest that future clinical trials should compare between carvedilol and combination of EVL and traditional NSBBs (*i.e*., propranolol or nadolol) or carvedilol to enrich our understanding about efficacy of carvedilol for the prevention of esophageal varices rebleeding.
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